Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation

Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy

(2019) Yue Song et al.   Immunotherapy

The next generation of immunotherapy: keeping lung cancer in check

(2017) Ashwin Somasundaram et al.   Journal of Hematology & Oncology

Cancer Immunotherapy: Whence and Whither

(2017) Peter J. Stambrook et al.   MOLECULAR CANCER RESEARCH

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

The SCF β-TRCP E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis

(2017) Kouhei Shimizu et al.   Science Signaling

The SCF β-TRCP E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis

(2017) Kouhei Shimizu et al.   Science Signaling

Combination immunotherapy: a road map

(2017) Patrick A. Ott et al.   Journal for ImmunoTherapy of Cancer

Deubiquitination and Stabilization of PD-L1 by CSN5

(2016) Seung-Oe Lim et al.   CANCER CELL

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment

(2016) Puyu Shi et al.   CANCER LETTERS

Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity

(2016) Laurent Beziaud et al.   CANCER RESEARCH

Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma

(2016) Yukiyoshi Hirayama et al.   CANCER SCIENCE

Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer

(2016) Kazuhiko Shien et al.   LUNG CANCER

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

(2016) Chia-Wei Li et al.   Nature Communications

Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers

(2016) E. C. Moore et al.   Cancer Immunology Research

Evolving Perspectives of mTOR Complexes in Immunity and Transplantation

(2015) D. Fantus et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells

(2015) Weilong Yao et al.   CANCER LETTERS

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

(2015) Kristin J. Lastwika et al.   CANCER RESEARCH

mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation

(2015) Junghui Koo et al.   MOLECULAR AND CELLULAR BIOLOGY

Maintaining Glycogen Synthase Kinase-3 Activity Is Critical for mTOR Kinase Inhibitors to Inhibit Cancer Cell Growth

(2014) J. Koo et al.   CANCER RESEARCH

mTOR signaling, Tregs and immune modulation

(2014) Nicole M Chapman et al.   Immunotherapy

Blockade of mTOR Signaling via Rapamycin Combined with Immunotherapy Augments Antiglioma Cytotoxic and Memory T-Cell Functions

(2014) Y. Mineharu et al.   MOLECULAR CANCER THERAPEUTICS

mTOR inhibition improves immune function in the elderly

(2014) J. B. Mannick et al.   Science Translational Medicine

mTOR kinase inhibitors as potential cancer therapeutic drugs

(2013) Shi-Yong Sun   CANCER LETTERS

mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA

(2013) M. Diken et al.   Cancer Immunology Research

Inhibition of Mechanistic Target of Rapamycin Promotes Dendritic Cell Activation and Enhances Therapeutic Autologous Vaccination in Mice

(2012) E. Amiel et al.   JOURNAL OF IMMUNOLOGY

TNF-α and TGF-β Counter-Regulate PD-L1 Expression on Monocytes in Systemic Lupus Erythematosus

(2012) Jing-Ni Ou et al.   Scientific Reports

Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors

(2011) Diana L. Thomas et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors

(2011) Yan-Jie Zhang et al.   DRUG DISCOVERY TODAY

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

(2011) Seth A. Wander et al.   JOURNAL OF CLINICAL INVESTIGATION

c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL

(2011) Lei Fu et al.   Molecular Cancer

DEPTOR, an mTOR Inhibitor, Is a Physiological Substrate of SCFβTrCP E3 Ubiquitin Ligase and Regulates Survival and Autophagy

(2011) Yongchao Zhao et al.   MOLECULAR CELL

mTOR Generates an Auto-Amplification Loop by Triggering the βTrCP- and CK1α-Dependent Degradation of DEPTOR

(2011) Shanshan Duan et al.   MOLECULAR CELL

mTOR Drives Its Own Activation via SCFβTrCP-Dependent Degradation of the mTOR Inhibitor DEPTOR

(2011) Daming Gao et al.   MOLECULAR CELL

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

The role of mTOR in memory CD8+ T-cell differentiation

(2010) Koichi Araki et al.   IMMUNOLOGICAL REVIEWS

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

(2010) C A Sparks et al.   ONCOGENE

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

(2009) Robert J. Amato et al.   CANCER

mTOR regulates memory CD8 T-cell differentiation

(2009) Koichi Araki et al.   NATURE

Enhancing Mammalian Target of Rapamycin (mTOR)-Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation

(2008) X. Wang et al.   CANCER RESEARCH

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET